Ofatumumab is under clinical development by Novartis and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ofatumumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ofatumumab overview
Ofatumumab (Arzerra) is an antibody. It is formulated as injection solution for intravenous route of administration. It is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) refractory to fludarabine and alemtuzumab. Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. Arzerra is used to treat chronic lymphocytic leukaemia (CLL). Arzerra indicated for the treatment of chronic lymphocytic leukaemia relapsed or refractory cd20 positive, for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. Arzerra in combination with fludarabine and cyclophosphamide (FC) is indicated for the treatment of patients with relapsed chronic lymphocytic leukaemia (CLL).
Ofatumumab in combination with bendamustine is under development for the treatment of follicular lymphoma relapsing multiple sclerosis including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), and recurrent multiple sclerosis. The drug candidate is also under development for acute lymphoblastic leukemia as first-line therapy. It was under development for the treatment of refractory non-Hodgkin’s lymphoma, pemphigus vulgaris, rheumatoid arthritis (RA), indolent B-cell non-Hodgkin's lymphoma, extranodal marginal zone B-Cell lymphoma, chronic obstructive pulmonary disease (COPD) and diffuse large B-cell lymphoma (relapsed and refractory patients). It is administered orally and subcutaneously.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Ofatumumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
